# A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

> **NCT05137262** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **OTHER:** Abiraterone acetate
- **DRUG:** Durvalumab
- **DRUG:** Methotrexate
- **DRUG:** Vinblastine
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05137262
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-13
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05137262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05137262, "A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05137262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*